David Alan Campbell - 02 Jan 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: President and CEO, Director
Signature: /s/ James Pennington, Attorney-in-Fact
Issuer symbol: JANX
Transactions as of: 02 Jan 2026
Net transactions value: -$110,829
Form type: 4
Filing time: 02 Jan 2026, 21:00:14 UTC
Previous filing: 08 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Campbell David Alan	President and CEO, Director	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO	/s/ James Pennington, Attorney-in-Fact	02 Jan 2025	0001864158

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Sale	$110,829	-8,072	-2.8%	$13.73	284,982	02 Jan 2026	Direct	F1
transaction	JANX	Common Stock	Award	$0	+96,600	+34%	$0.000000	381,582	02 Jan 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+338,100		$0.000000	338,100	02 Jan 2026	Common Stock	338,100	$13.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F3	25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.